MY152178A - Substituted 8-[6-amino-3-pyridyl]xanthines - Google Patents

Substituted 8-[6-amino-3-pyridyl]xanthines

Info

Publication number
MY152178A
MY152178A MYPI20084937A MY152178A MY 152178 A MY152178 A MY 152178A MY PI20084937 A MYPI20084937 A MY PI20084937A MY 152178 A MY152178 A MY 152178A
Authority
MY
Malaysia
Prior art keywords
xanthines
pyridyl
amino
substituted
compositions
Prior art date
Application number
Other languages
English (en)
Inventor
Wang Guoquan
Robert D Thompson
Jayson M Rieger
Original Assignee
Dogwood Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dogwood Pharmaceuticals Inc filed Critical Dogwood Pharmaceuticals Inc
Publication of MY152178A publication Critical patent/MY152178A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MYPI20084937 2006-06-16 2007-06-13 Substituted 8-[6-amino-3-pyridyl]xanthines MY152178A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80503006P 2006-06-16 2006-06-16
US80556406P 2006-06-22 2006-06-22
US11/811,823 US7884100B2 (en) 2006-06-16 2007-06-12 Substituted 8-[6-amino-3-pyridyl]xanthines

Publications (1)

Publication Number Publication Date
MY152178A true MY152178A (en) 2014-08-15

Family

ID=56290980

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20084937 MY152178A (en) 2006-06-16 2007-06-13 Substituted 8-[6-amino-3-pyridyl]xanthines

Country Status (18)

Country Link
US (2) US7884100B2 (OSRAM)
EP (1) EP2029143B1 (OSRAM)
JP (1) JP5417558B2 (OSRAM)
KR (1) KR101413404B1 (OSRAM)
CN (1) CN103145712A (OSRAM)
AU (1) AU2007261568B2 (OSRAM)
BR (1) BRPI0712001B8 (OSRAM)
CA (1) CA2655598C (OSRAM)
DK (1) DK2029143T3 (OSRAM)
EA (1) EA016791B1 (OSRAM)
ES (1) ES2548437T3 (OSRAM)
HU (1) HUE026457T2 (OSRAM)
IL (1) IL195916A (OSRAM)
MX (1) MX2008015954A (OSRAM)
MY (1) MY152178A (OSRAM)
NZ (1) NZ597222A (OSRAM)
PL (1) PL2029143T3 (OSRAM)
PT (1) PT2029143E (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7317017B2 (en) * 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
PT1658291E (pt) * 2003-08-25 2013-10-21 Dogwood Pharmaceuticals Inc 8-heteroarilxantinas substituídas
US7598379B2 (en) * 2005-02-25 2009-10-06 Pgx Health, Llc Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines
US7579348B2 (en) * 2005-02-25 2009-08-25 Pgxhealth, Llc Derivatives of 8-substituted xanthines
US7618962B2 (en) * 2005-02-25 2009-11-17 Pgx Health, Llc Pyrazolyl substituted xanthines
US7884100B2 (en) * 2006-06-16 2011-02-08 Pgxhealth, Llc Substituted 8-[6-amino-3-pyridyl]xanthines
US7875608B2 (en) * 2007-12-17 2011-01-25 Thompson Robert D Substituted 8-[6-amino-3pyridyl]xanthines
JP2024521704A (ja) 2021-05-18 2024-06-04 アドベイト，エルエルシー Ａ２ｂアンタゴニストとしての環状アミド含有ピリジルキサンチン

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6117878A (en) * 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
US6060481A (en) 1998-05-28 2000-05-09 The Penn State Research Foundation Method for improving insulin sensitivity using an adenosine receptor antagonist
GB9817623D0 (en) 1998-08-13 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
EP1255550A2 (en) * 2000-02-17 2002-11-13 Cv Therapeutics, Inc. Method for identifying and using a 2b adenosine receptor antagonists to mediate mammalian cell proliferation
HU229504B1 (hu) 2001-11-09 2014-01-28 Gilead Sciences A2B-adenozinreceptor-antagonisták
US6977300B2 (en) 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US7317017B2 (en) * 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US7304070B2 (en) 2001-11-09 2007-12-04 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
KR20040080939A (ko) 2002-02-01 2004-09-20 킹 파머슈티칼스 리서치 앤드 디벨로프먼트 아이엔씨 8-헤테로아릴 크산틴 아데노신 에이투비 수용체 길항제
US7034070B2 (en) * 2002-09-27 2006-04-25 Vincent Chuang Arylalkyl aminofunctional silanes for epoxy laminates
US7148229B2 (en) 2003-02-19 2006-12-12 Hoffman-La Roche Inc. Sulfonamide substituted xanthine derivatives
PT1658291E (pt) 2003-08-25 2013-10-21 Dogwood Pharmaceuticals Inc 8-heteroarilxantinas substituídas
ES2387653T3 (es) 2004-09-01 2012-09-27 Gilead Sciences, Inc. Procedimiento de cicatrización de heridas utilizando antagonistas del receptor de adenosina A2B
US20060053029A1 (en) 2004-09-03 2006-03-09 Butler Keith R Methods and systems for providing an enterprise supply management portal
RU2391103C2 (ru) 2004-10-15 2010-06-10 Си Ви Терапьютикс, Инк. Способ предупреждения и лечения ремоделирования дыхательных путей и воспаления легких с применением антагонистов аденозиновых рецепторов a2b
US7618962B2 (en) 2005-02-25 2009-11-17 Pgx Health, Llc Pyrazolyl substituted xanthines
US7601723B2 (en) * 2005-02-25 2009-10-13 Pgx Health, Llc Pyridyl substituted xanthines
US7579348B2 (en) * 2005-02-25 2009-08-25 Pgxhealth, Llc Derivatives of 8-substituted xanthines
US7598379B2 (en) * 2005-02-25 2009-10-06 Pgx Health, Llc Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines
CN101198608B (zh) 2005-06-16 2011-04-27 吉利德帕洛阿尔托股份有限公司 A2b腺苷受体拮抗剂的前药
RU2457842C2 (ru) * 2006-03-17 2012-08-10 Гайлид Пало Альто, Инк. Способ предотвращения и лечения болезни печени с использованием антагонистов рецептора аденозина a2b
CA2652858A1 (en) * 2006-06-15 2007-12-27 Targeted Genetics Corporation Methods for treating target joints in inflammatory arthritis using aav vectors encoding a tnf antagonist
US7884100B2 (en) 2006-06-16 2011-02-08 Pgxhealth, Llc Substituted 8-[6-amino-3-pyridyl]xanthines
US7767685B2 (en) 2006-06-29 2010-08-03 King Pharmaceuticals Research And Development, Inc. Adenosine A2B receptor antagonists
US7875608B2 (en) * 2007-12-17 2011-01-25 Thompson Robert D Substituted 8-[6-amino-3pyridyl]xanthines
BRPI0909157A2 (pt) 2008-03-26 2015-11-24 Advinus Therapeutics Private Ltd compostos heterocíclicos como antagonistas de receptores de adenosina

Also Published As

Publication number Publication date
PL2029143T3 (pl) 2015-12-31
US8258142B2 (en) 2012-09-04
US20080004292A1 (en) 2008-01-03
AU2007261568A1 (en) 2007-12-27
EP2029143A2 (en) 2009-03-04
JP2010500284A (ja) 2010-01-07
AU2007261568B2 (en) 2013-05-16
PT2029143E (pt) 2015-10-20
CA2655598A1 (en) 2007-12-27
EP2029143B1 (en) 2015-07-08
ES2548437T3 (es) 2015-10-16
IL195916A0 (en) 2009-09-01
CN103145712A (zh) 2013-06-12
IL195916A (en) 2015-06-30
BRPI0712001A2 (pt) 2012-01-10
EA200900010A1 (ru) 2009-10-30
NZ597222A (en) 2013-06-28
HUE026457T2 (en) 2016-05-30
KR20090029268A (ko) 2009-03-20
BRPI0712001B8 (pt) 2021-05-25
BRPI0712001B1 (pt) 2020-04-07
CA2655598C (en) 2014-10-28
US20110082139A1 (en) 2011-04-07
JP5417558B2 (ja) 2014-02-19
DK2029143T3 (en) 2015-09-21
MX2008015954A (es) 2009-03-06
US7884100B2 (en) 2011-02-08
EP2029143A4 (en) 2009-07-15
KR101413404B1 (ko) 2014-06-27
EA016791B1 (ru) 2012-07-30

Similar Documents

Publication Publication Date Title
WO2005021548A3 (en) Substituted 8-heteroaryl xanthines
MY152178A (en) Substituted 8-[6-amino-3-pyridyl]xanthines
WO2008031556A3 (en) 2 amino-pyrimidine derivatives as h4 receptor antagonists, processes for preparing them and their use in pharmaceutical compositions
ZA200800353B (en) Pyrazine derivatives useful as adenosine receptor antagonists
BRPI0813218A2 (pt) Composto, composição farmacêutica que o contém como princípio ativo e uso do composto.
IL178396A0 (en) Condensed pyridine derivatives useful as a28 adenosine receptor antagonists
IL195006A0 (en) Thiazolo-pyramidine/pyridine urea derivatives as adenosine a2b receptor antagonists
WO2008021851A3 (en) Novel compounds as antagonists or inverse agonists for opioid receptors
WO2006091898A3 (en) Pyrazolyl substituted xanthines
ZA200801945B (en) Novelimidazolecarboxamide derivatives as fructose-1,6-bisphosphatase inhibitors, and pharmaceutical compositions comprising same
BRPI0910182B8 (pt) composto de fórmula (i), composição farmacêutica e uso de um composto
HU0400405D0 (en) Novel compounds
ATE461932T1 (de) Pyrazoloä4,3-eü-1,2,4-triazoloä1,5-cüpyrimidine als antagonisten des adenosin-a2a-rezeptors
MX2009004746A (es) Derivados de 1,2,4-triazol como inhibidores del receptor sigma.
WO2009043320A3 (en) Substituted 6-(alkylbenzylamino)purine derivatives for use as cytokinin receptor antagonists and preparations containing these derivatives
WO2008020405A3 (en) Azetidine compounds as orexin receptor antagonists
WO2007067506A3 (en) 2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors
IL188103A0 (en) Prodrugs of a2b adenosine receptor antagonists
WO2008011007A3 (en) Selective antagonists of a2a adenosine receptors
TN2009000040A1 (en) 5,6-bisaryl-2-pyridine-carboxamide derivatives, preparation and application thereof in therapeutics as urotensin ii receptor antagonists
UA105164C2 (en) Substituted 8-[6-amino-3-pyridyl]xanthines
WO2005040155A8 (en) Pyrimidin-2-amine derivates and their use as a2b adenosine receptor antagonists
WO2008027585A3 (en) Pyrrolo[3,2-d]pyrimidines that are selective antagonists of a2b adenosine receptors
WO2008116185A3 (en) Substituted pyrimidines as adenosine receptor antagonists
MXPA05013149A (es) Derivados de imidazol como antagonistas del receptor de glutamato.